Albumin Administration in Acute Ischemic Stroke: Safety Analysis of the ALIAS Part 2 Multicenter Trial

Michael D Hill, Renee H Martin, Yuko Y Palesch, Claudia S Moy, Diego Tamariz, Karla J Ryckborst, Elizabeth B Jones, David Weisman, Creed Pettigrew, Myron D Ginsberg, Michael D Hill, Renee H Martin, Yuko Y Palesch, Claudia S Moy, Diego Tamariz, Karla J Ryckborst, Elizabeth B Jones, David Weisman, Creed Pettigrew, Myron D Ginsberg

Abstract

Background: Albumin treatment of ischemic stroke was associated with cardiopulmonary adverse events in previous studies and a low incidence of intracranial hemorrhage. We sought to describe the neurological and cardiopulmonary adverse events in the ALIAS Part 2 Multicenter Trial.

Methods: Ischemic stroke patients, aged 18-83 and a baseline NIHSS ≥ 6, were randomized to treatment with ALB or saline control within 5 hours of stroke onset. Neurological adverse events included symptomatic intracranial hemorrhage, hemicraniectomy, neurological deterioration and neurological death. Cardiopulmonary adverse events included pulmonary edema/congestive heart failure, acute coronary syndromes, atrial fibrillation, pneumonia and pulmonary thromboembolism.

Results: Among 830 patients, neurological and cardiopulmonary adverse events were not differentially associated with poor outcome between ALB and saline control subjects. The rate of symptomatic intracranial hemorrhage in the first 24h was low overall (2.9%, 24/830) but more common in the ALB treated subjects (RR = 2.4, CI95 1.01-5.8). The rate of pulmonary edema/CHF in the first 48h was 7.9% (59/830) and was more common among ALB treated subjects (RR = 10.7, CI95 4.3-26.6); this complication was expected and was satisfactorily managed with mandated diuretic administration and intravenous fluid guidelines. Troponin elevations in the first 48h were common, occurring without ECG change or cardiac symptoms in 52 subjects (12.5%).

Conclusions: ALB therapy was associated with an increase in symptomatic ICH and pulmonary edema/congestive heart failure but this did not affect final outcomes. Troponin elevation occurs routinely in the first 48 hours after acute ischemic stroke.

Trial registration: ClincalTrials.gov NCT00235495.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001;32(2):553–60. .
    1. Ginsberg M, Belayev L, Bazan N, Marcheselli V, Hill M, Palesch Y, et al. Albumin-based neurotherapeutics for acute ischemic stroke: from bench to bedside In: J K, S K, editors. Pharmacology of Cerebral Ischemia. Stuttgart: Medpharm Scientific Publishers; 2004. p. 421–33.
    1. Belayev L, Zhao W, Pattany PM, Weaver RG, Huh PW, Lin B, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke. 1998;29(12):2587–99. .
    1. Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, Riyamongkol P, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke. 2002;33(4):1077–84. .
    1. Defazio RA, Zhao W, Deng X, Obenaus A, Ginsberg MD. Albumin therapy enhances collateral perfusion after laser-induced middle cerebral artery branch occlusion: a laser speckle contrast flow study. J Cereb Blood Flow Metab. 2012;32(11):2012–22. 10.1038/jcbfm.2012.102
    1. Nimmagadda A, Park HP, Prado R, Ginsberg MD. Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study. Stroke. 2008;39(1):198–204. Epub 2007/11/23. STROKEAHA.107.495598 [pii] 10.1161/STROKEAHA.107.495598
    1. Park HP, Nimmagadda A, DeFazio RA, Busto R, Prado R, Ginsberg MD. Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: a two-photon laser-scanning microscopy study. Stroke. 2008;39(5):1556–62. Epub 2008/03/08. STROKEAHA.107.502195 [pii] 10.1161/STROKEAHA.107.502195
    1. Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D. The ALIAS phase I trial: A dose-escalation and safety study of albumin therapy for acute ischemic stroke. Stroke. 2005;36(2):420–. .
    1. Hill MD, Moy CS, Palesch YY, Martin R, Dillon CR, Waldman BD, et al. The albumin in acute stroke trial (ALIAS); design and methodology. Int J Stroke. 2007;2(3):214–9. Epub 2008/08/19. 10.1111/j.1747-4949.2007.00143.x .
    1. Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke—I: Physiological responses and safety results. Stroke. 2006;37(8):2100–6. Epub 2006/07/01. 10.1161/01.STR.0000231388.72646.05 .
    1. Ginsberg MD, Palesch YY, Martin RH, Hill MD, Moy CS, Waldman BD, et al. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke. 2011;42(1):119–27. 10.1161/STROKEAHA.110.596072
    1. Hill MD, Martin RH, Palesch YY, Tamariz D, Waldman BD, Ryckborst KJ, et al. The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis. Stroke. 2011;42(6):1621–5. Epub 2011/05/07. 10.1161/STROKEAHA.110.610980
    1. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. 2013;12(11):1049–58. Epub 2013/10/01. 10.1016/S1474-4422(13)70223-0
    1. Katsanos AH, Korantzopoulos P, Tsivgoulis G, Kyritsis AP, Kosmidou M, Giannopoulos S. Electrocardiographic abnormalities and cardiac arrhythmias in structural brain lesions. Int J Cardiol. 2013;167(2):328–34. 10.1016/j.ijcard.2012.06.107 .
    1. Anders B, Alonso A, Artemis D, Schafer A, Ebert A, Kablau M, et al. What does elevated high-sensitive troponin I in stroke patients mean: concomitant acute myocardial infarction or a marker for high-risk patients? Cerebrovascular diseases. 2013;36(3):211–7. 10.1159/000353875 .
    1. Kral M, Sanak D, Veverka T, Hutyra M, Vindis D, Kuncarova A, et al. Troponin T in acute ischemic stroke. The American journal of cardiology. 2013;112(1):117–21. 10.1016/j.amjcard.2013.02.067 .
    1. Jensen JK, Ueland T, Aukrust P, Antonsen L, Kristensen SR, Januzzi JL, et al. Highly sensitive troponin T in patients with acute ischemic stroke. European neurology. 2012;68(5):287–93. 10.1159/000341340 .
    1. Beaulieu-Boire I, Leblanc N, Berger L, Boulanger JM. Troponin elevation predicts atrial fibrillation in patients with stroke or transient ischemic attack. Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association. 2013;22(7):978–83. 10.1016/j.jstrokecerebrovasdis.2012.01.008 .
    1. Song HS, Back JH, Jin DK, Chung PW, Moon HS, Suh BC, et al. Cardiac troponin T elevation after stroke: relationships between elevated serum troponin T, stroke location, and prognosis. Journal of clinical neurology. 2008;4(2):75–83. 10.3988/jcn.2008.4.2.75
    1. Blackshear JL, Cutlip DE, Roubin GS, Hill MD, Leimgruber PP, Begg RJ, et al. Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial. Circulation. 2011;123(22):2571–8. Epub 2011/05/25. 10.1161/CIRCULATIONAHA.110.008250
    1. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke; a journal of cerebral circulation. 2010;41(1):48–53. 10.1161/STROKEAHA.109.561712 .
    1. Ginsberg MD, Martin RH, Hill MD, Palesch YY, Yeatts S, Moy CS, et al. The Albumin in Acute Stroke (ALIAS) Trial: Part 1 Safety Analysis. Stroke. 2010;41(4):E228–E. .
    1. Weimar C, Ali M, Lees KR, Bluhmki E, Donnan GA, Diener HC, et al. The Virtual International Stroke Trials Archive (VISTA): results and impact on future stroke trials and management of stroke patients. Int J Stroke. 2010;5(2):103–9. 10.1111/j.1747-4949.2010.00414.x .
    1. Belayev L, Saul I, Busto R, Danielyan K, Vigdorchik A, Khoutorova L, et al. Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. Stroke. 2005;36(2):326–31. 10.1161/01.STR.0000152949.31366.3d .
    1. Skhirtladze K, Base EM, Lassnigg A, Kaider A, Linke S, Dworschak M, et al. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery. British journal of anaesthesia. 2014;112(2):255–64. 10.1093/bja/aet348 .
    1. Nielsen VG. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions. Acta anaesthesiologica Scandinavica. 2005;49(8):1163–71. 10.1111/j.1399-6576.2005.00733.x .
    1. Hanna J, Winstedt D, Schott U. Fibrinogen and FXIII dose response effects on albumin-induced coagulopathy. Scandinavian journal of clinical and laboratory investigation. 2013;73(7):553–62. 10.3109/00365513.2013.821710 .
    1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29. Epub 2008/09/26. 10.1056/NEJMoa0804656 .

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel